Sonnet BioTherapeutics Holdings, Inc. / "Executive Compensation" | Tables in SEC filings

SONN Sonnet BioTherapeutics Holdings, Inc.

Annual report

PART I	1.	Business	4
	1A.	Risk Factors	38
	1B.	Unresolved Staff Comments	81
	2.	Properties	82
	3.	Legal Proceedings	82
	4.	Mine Safety Disclosures	82
PART II	5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	83
	7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	84
	7A.	Quantitative and Qualitative Disclosures About Market Risk	95
	8.	Financial Statements and Supplementary Data	96
	9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	121
	9A.	Controls and Procedures	121
	9B.	Other Information	121
	9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	121
PART III	10.	Directors, Executive Officers and Corporate Governance	122
	11.	Executive Compensation	127
	12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	131
	13.	Certain Relationships and Related Transactions, and Director Independence	133
	14.	Principal Accounting Fees and Services	133
PART IV	15.	Exhibits, Financial Statement Schedules	135
	16.	Form 10-K Summary	135

Year	Summary Compensation Table Total for Dr. Mohan(1)		Compensation Actually Paid to Dr. Mohan(3)		Average Summary Compensation Table Total for Non-PEO NEOs(2)		Average Compensation Actually Paid to Non-PEO NEOs(3)		Value of Initial Fixed $100 Investment Based On Total Shareholder Return (“TSR”)(4)		Net Income (Loss) (millions)(5)
(a)	(b)		(c)		(d)		(e)		(f)		(g)
2023		1,022,720		508,988		622,830		415,486		8.81		(18,832,694)
2022		1,005,393		676,266		609,894		262,233		16.15		(29,721,841)

Table search / Sonnet BioTherapeutics Holdings, Inc. / "Executive Compensation"